1
EXHIBIT 10.8
[ALLERGAN LOGO]
March 5, 2001
Xxxxxxx X. Xxxxxxxx
Chairman of the Board
Allergan Specialty Therapeutics, Inc.
0000 Xxxxxx
Xxxxxx, XX 00000
Dear Xx. Xxxxxxxx:
Pursuant to this letter agreement by and between Allergan, Inc. ("Allergan") and
Allergan Specialty Therapeutics, Inc. ("ASTI"), Exhibit A to the License Option
Agreement dated March 6, 1998, by and between Allergan and ASTI is amended as
follows:
Section 3.1(a) of the Exhibit A is amended to add the following provisions after
3.1(a)(ii):
"(iii) Notwithstanding any other provision of this Agreement, including
Section 3.1(a)(I) and (ii), Allergan shall pay to ASTI a royalty of fifteen (15)
percent (15%) of Allergan's Net Sales of the following ASTI Products, if such
ASTI Product has become a Licensed Product:
Brimo Timolol Combo Eyecare Ocular Hypertension/Primary Angle Glaucoma
Keto Reformulation Eyecare Post surgical Pain
Alpha 2 Pain New Technologies Chronic Pain
Photo Dynamic Therapy Eyecare Age Related Macular Degeneration
AGN 195795 Eyecare Glaucoma"
Additionally, by this letter agreement, Allergan, on the one hand, and ASTI, on
the other, confirm that Exhibit A attached hereto accurately reflects the
current ASTI Products and Pre-Selection Work Projects of ASTI.
Please acknowledge your acceptance of the terms of this letter agreement by
signing below.
Very truly yours,
/s/ XXXX XXXXXX
-----------------------
Xxxx Xxxxxx ACCEPTED AND AGREED:
Allergan Specialty Therapeutics, Inc.
By: /s/ XXXXXXX X. XXXXXXXX
---------------------------------
Xxxxxxx X. Xxxxxxxx, Chairman
